Compare Keysight Technologies Inc (KEYS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs GeneDx Holdings Corp — how do they compare? Keysight Technologies Inc trades at $329.98 (market cap $53.68B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Keysight Technologies Inc is far larger — about 29.8× GeneDx Holdings Corp's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| KEYS | WGS | |
|---|---|---|
Market Cap | $53.68B | $1.80B |
Sector | Technology | Technology |
52-Week High | $373.34 | $167.51 |
52-Week Low | $158.51 | $34.51 |
Enterprise Value | $54.03B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $328.11, up 3.87% today, with strong earnings beats in recent quarters. The stock shows a bearish technical signal despite positive analyst sentiment, with 81% buy ratings and a $396.56 consensus price target. Recent developments include partnerships with the European Space Agency and acquisitions in photonics design, positioning the company for growth in 5G and AI-driven markets.
Outlook remains positive due to robust fundamentals and strategic expansions, but high valuation multiples and technical weakness pose risks. Revenue is projected to grow to $6.1B in 2026, with net income margin improving to 17.31%. Investors should weigh strong profitability against elevated P/E of 50.58 and current bearish momentum.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
